Previous 10 | Next 10 |
2024-02-14 14:13:51 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential Ironwood Pharmaceuticals expects 2024 revenue to be below consensus Seeking Alpha’s Quant Rating on Ironwood Pharmaceuticals ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 15, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (...
2024-01-31 13:59:32 ET Summary Ironwood Pharmaceuticals has established itself as a leader in the gastrointestinal healthcare space with its innovative products and pipeline development. The demand for LINZESS, a therapy for irritable bowel syndrome, is increasing, contributing to...
– Newly published data highlights additional efficacy endpoints from trial – – Linaclotide is the first and only FDA-approved prescription therapy for children and adolescents aged 6-17 years with functional constipation – Ironwood Pharmaceuticals...
2024-01-08 07:53:55 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2023 Earnings Call Transcript Ironwood Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Ironwood Pharmaceuticals: The Right Play Now Jefferies...
– Expects high-single digit percentage LINZESS® EUTRx prescription demand growth in 2024 – – Expects 2024 adjusted EBITDA of greater than $150 million – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare compan...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 11:15 a.m. Pacific Time / 2:15 p.m. Eastern Time at The Westin St. Fran...
2024-01-02 12:13:42 ET More on Markets S&P, Dow, Nasdaq dip, yields jump to kick off 2024 Gap between all-time highs for the S&P 500 is the sixth longest in history 2024 Analyst Outlook: Julian Lin On What's Next For AI, Large Cap Tech And Cannabis Investing ...
2023-12-15 01:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, today announced the successful completion of the squeeze-out merger under Swiss law (the “Squeeze-Out Merger”) pursuant to which VectivBio Holding AG (“VectivBio”...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-22 07:00:07 ET Mohit Bansal from Wells Fargo issued a price target of $14.00 for IRWD on 2024-05-22 05:13:00. The adjusted price target was set to $14.00. At the time of the announcement, IRWD was trading at $6.78. The overall price target consensus is at $16.00 ...